Literature DB >> 21968397

A disulfide-free single-domain V(L) intrabody with blocking activity towards huntingtin reveals a novel mode of epitope recognition.

André Schiefner1, Lorenz Chatwell, Jana Körner, Irmgard Neumaier, David W Colby, Rudolf Volkmer, K Dane Wittrup, Arne Skerra.   

Abstract

We present the crystal structure and biophysical characterization of a human V(L) [variable domain immunoglobulin (Ig) light chain] single-domain intrabody that binds to the huntingtin (Htt) protein and has been engineered for antigen recognition in the absence of its intradomain disulfide bond, otherwise conserved in the Ig fold. Analytical ultracentrifugation demonstrated that the αHtt-V(L) 12.3 domain is a stable monomer under physiological conditions even at concentrations >20 μM. Using peptide SPOT arrays, we identified the minimal binding epitope to be EKLMKAFESLKSFQ, comprising the N-terminal residues 5-18 of Htt and including the first residue of the poly-Gln stretch. X-ray structural analysis of αHtt-V(L) both as apo protein and in the presence of the epitope peptide revealed several interesting insights: first, the role of mutations acquired during the combinatorial selection process of the αHtt-V(L) 12.3 domain-initially starting from a single-chain Fv fragment-that are responsible for its stability as an individually soluble Ig domain, also lacking the disulfide bridge, and second, a previously unknown mode of antigen recognition, revealing a novel paratope. The Htt epitope peptide adopts a purely α-helical structure in the complex with αHtt-V(L) and is bound at the base of the complementarity-determining regions (CDRs) at the concave β-sheet that normally gives rise to the interface between the V(L) domain and its paired V(H) (variable domain Ig heavy chain) domain, while only few interactions with CDR-L1 and CDR-L3 are formed. Notably, this noncanonical mode of antigen binding may occur more widely in the area of in vitro selected antibody fragments, including other Ig-like scaffolds, possibly even if a V(H) domain is present.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21968397     DOI: 10.1016/j.jmb.2011.09.034

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  12 in total

Review 1.  Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins.

Authors:  David C Butler; Julie A McLear; Anne Messer
Journal:  Prog Neurobiol       Date:  2011-11-18       Impact factor: 11.685

Review 2.  Physical chemistry of polyglutamine: intriguing tales of a monotonous sequence.

Authors:  Ronald Wetzel
Journal:  J Mol Biol       Date:  2012-01-27       Impact factor: 5.469

3.  Application of antihelix antibodies in protein structure determination.

Authors:  Ji Won Kim; Songwon Kim; Haerim Lee; Geunyoung Cho; Sun Chang Kim; Hayyoung Lee; Mi Sun Jin; Jie-Oh Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-01       Impact factor: 11.205

4.  Kinetically competing huntingtin aggregation pathways control amyloid polymorphism and properties.

Authors:  Murali Jayaraman; Rakesh Mishra; Ravindra Kodali; Ashwani K Thakur; Leonardus M I Koharudin; Angela M Gronenborn; Ronald Wetzel
Journal:  Biochemistry       Date:  2012-03-20       Impact factor: 3.162

5.  Teaching an old scaffold new tricks: monobodies constructed using alternative surfaces of the FN3 scaffold.

Authors:  Akiko Koide; John Wojcik; Ryan N Gilbreth; Robert J Hoey; Shohei Koide
Journal:  J Mol Biol       Date:  2011-12-16       Impact factor: 5.469

Review 6.  Discovery of novel candidate therapeutics and diagnostics based on engineered human antibody domains.

Authors:  Weizao Chen; Rui Gong; Tianlei Ying; Ponraj Prabakaran; Zhongyu Zhu; Yang Feng; Dimiter S Dimitrov
Journal:  Curr Drug Discov Technol       Date:  2014-03

Review 7.  Intrabodies as neuroprotective therapeutics.

Authors:  Anne Messer; Shubhada N Joshi
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

8.  Bifunctional anti-huntingtin proteasome-directed intrabodies mediate efficient degradation of mutant huntingtin exon 1 protein fragments.

Authors:  David C Butler; Anne Messer
Journal:  PLoS One       Date:  2011-12-22       Impact factor: 3.240

9.  Structure of a single-chain Fv bound to the 17 N-terminal residues of huntingtin provides insights into pathogenic amyloid formation and suppression.

Authors:  Erwin De Genst; Dimitri Y Chirgadze; Fabrice A C Klein; David C Butler; Dijana Matak-Vinković; Yvon Trottier; James S Huston; Anne Messer; Christopher M Dobson
Journal:  J Mol Biol       Date:  2015-04-08       Impact factor: 5.469

10.  Antibody light chain variable domains and their biophysically improved versions for human immunotherapy.

Authors:  Dae Young Kim; Rebecca To; Hiba Kandalaft; Wen Ding; Henk van Faassen; Yan Luo; Joseph D Schrag; Nadereh St-Amant; Mary Hefford; Tomoko Hirama; John F Kelly; Roger MacKenzie; Jamshid Tanha
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.